A Pill for Sleep Apnea? FDA Approves First Drug Treatment for Millions Struggling to Breathe at Night

The U.S. Food and Drug Administration has approved the first-ever medication to treat obstructive sleep apnea (OSA), marking a historic breakthrough for people who struggle with this breathing disorder. Zepbound (tirzepatide), previously known as a weight-loss drug, received approval on December 20, 2024, specifically for moderate to severe sleep apnea in adults with obesity.

This approval comes at a crucial time, as new research reveals the far-reaching consequences of untreated sleep apnea. A major study of over 11 million veterans found that people with sleep apnea face nearly double the risk of developing Parkinson's disease within six years—but early treatment with continuous positive airway pressure (CPAP) machines reduced this risk by about 30%.

How Does This New Sleep Apnea Medication Work?

Unlike traditional CPAP machines that force air through blocked airways, Zepbound tackles sleep apnea from a different angle. The medication activates hormone receptors in the intestine—specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)—to reduce appetite and food intake. By helping patients lose weight, the drug addresses one of the root causes of sleep apnea: excess tissue that blocks breathing passages during sleep.

In clinical trials involving 469 adults without type 2 diabetes, participants who received Zepbound experienced significant improvements in their apnea hypopnea index (AHI)—a measurement of how many times breathing stops or becomes shallow per hour during sleep. The studies tracked patients for 52 weeks, with some participants also using CPAP machines while others were unable or unwilling to use traditional breathing devices.

What Are the Side Effects and Risks?

Like all medications, Zepbound comes with potential side effects that patients should discuss with their healthcare providers. The most common issues include:

• Digestive Problems: Nausea, diarrhea, vomiting, constipation, and abdominal discomfort were frequently reported during clinical trials
• Physical Reactions: Injection site reactions, fatigue, burping, hair loss, and gastroesophageal reflux disease affected some participants
• Serious Warnings: The drug carries warnings for inflammation of the pancreas, gallbladder problems, low blood sugar, kidney injury, and potential thyroid tumors based on animal studies

"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical Care in the FDA's Center for Drug Evaluation and Research. "This is a major step forward for patients with obstructive sleep apnea."

Why Does Sleep Apnea Treatment Matter Beyond Better Sleep?

The connection between sleep apnea and serious health conditions extends far beyond feeling tired during the day. The recent veterans study revealed that untreated sleep apnea significantly increases the risk of Parkinson's disease, a neurodegenerative disorder affecting more than 1.1 million Americans. The research showed this risk remained even after controlling for other factors like high body mass index (BMI), diabetes, high blood pressure, depression, anxiety, and traumatic brain injuries.

"We know that people with Parkinson's have a lot of difficulties with sleep, and so it made sense that maybe sleep difficulties were happening even earlier, before the disease started," explained Dr. Lee Neilson, study co-author and a neurologist at the Portland VA Medical Center as well as an assistant professor at Oregon Health & Science University. "It also made sense that if you are not only not getting good sleep, but if your brain is not getting the right amount of oxygen night in and night out, that could be kind of one hit along the pathway to developing Parkinson's."

The FDA granted Zepbound Fast Track, Priority Review, and Breakthrough Therapy designations for this sleep apnea indication, reflecting the urgent need for new treatment options. For patients who struggle with CPAP machines—whether due to claustrophobia, discomfort, or other issues—this medication represents the first alternative that directly addresses the underlying condition rather than just managing symptoms.

However, researchers emphasize that the medication is specifically approved for adults with obesity who have moderate to severe sleep apnea, and it must be combined with a reduced-calorie diet and increased physical activity. The drug's effectiveness appears directly linked to weight loss, making it most suitable for patients whose sleep apnea is primarily related to excess weight.